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Gold-Catalyzed Cycloisomerization and Diels-Alder Reaction of 
1,4,9-Dienyne Esters to 3a,6-Methanoisoindole Esters with Pro-
Inflammatory Cytokine Antagonist Activity 
Dewi Susanti,[c] Li-Juan Liu,[d] Weidong Rao,[c] Sheng Lin,[e] Dik-Lung Ma,[e],* Chung-Hang Leung,[d],* 
and Philip Wai Hong Chan[a,b,c],* 
 
Abstract: A synthetic method to prepare 3a,6-methanoisoindole 
esters efficiently by gold(I)-catalyzed tandem 1,2-acyloxy 
migration/Nazarov cyclization followed by Diels-Alder reaction of 
1,4,9-dienyne esters is described. We also report the ability of one 
example to inhibit binding of tumor necrosis factor- (TNF-) to the 
tumor necrosis factor receptor 1 (TNFR1) site and TNF--induced 
nuclear factor -light-chain-enhancer of activated B cells (NF-B) 
activation in cell at a half-maximal inhibitory concentration (IC50) 
value of 10 M. Along with this is a study showing the isoindolyl 
derivative to exhibit low toxicity toward human hepatocellular liver 
carcinoma (HepG2) cells and its possible mode of activity based on 
molecular modeling analysis. 
Introduction 
Through its binding to the TNFR1 site, the pro-inflammatory 
cytokine TNF- acts as a central biological mediator for critical 
immune functions, including inflammation, infection, and 
antitumor responses in human cells.[1] The aberrant expression 
of TNF- has been implicated in an array of pathophysiologies 
that include cancer, cardiovascular, autoimmune, metabolic 
disorders and, in particular, chronic inflammatory diseases such 
as rheumatoid arthritis, psoriasis, refractory asthma and Crohn’s 
disease.[2] Current clinically approved treatments make use of 
the synthetic antibodies etanercept, infliximab, and adalimumab, 
which bind directly to TNF- and thus prevent its association 
with the TNFR1 site.[3] However, a main drawback of these 
protein agents is the need for intravenous administration and the 
potential to cause serious side effects such as provoking an 
autoimmune anti-antibody immune response and weakening of 
the immune system to opportunistic infections.[4] As a result, the 
development of alternative approaches such as small molecule-
based therapies has come under increasing scrutiny in recent 
years for TNF- inhibition. So far, this has led to the discovery of 
a number of small molecule inhibitors, the majority of which work 
by indirectly targeting TNF- by down-regulating the expression 
of the cytokine.[4,5] To our knowledge, those that bind directly to 
TNF- have, on the other hand, remained limited to the 
compounds shown in Figure 1 along with polysulfonated 
naphthylurea, suramin and its analogues.[6-10] For this reason, 
the development of new classes of small molecule antagonists 
of TNF- that directly target the cytokine and are non-toxic and 
thus suitable for therapeutic applications continues to be 
pursued. 
 
Figure 1. Small molecule antagonists that directly target TNF--TNFR1 
binding at the end of the template.[7-10] 
One of the most important strategies in organic synthesis for 
the efficient assembly of complex polycyclic systems is transition 
metal-catalyzed cyclization of unsaturated hydrocarbons.[11-25] 
This has owed as much to the ease in which substrates with 
various substitution patterns can be accessed as it has been to 
the ability to provide a wide range of structures from a single 
starting material by changing the catalyst and reaction 
conditions. An illustrative example of this is the impressive 
number of elegant methods to various synthetically useful cyclic 
compounds from gold-catalyzed cycloisomerization of 1,n-enyne 
esters.[12-19] Of particular interest is a small handful of works 
showing Au(I)-mediated 1,3- and 1,2-acyloxy migration of the 
respective 1,3- and 1,4-enyne esters 5 followed by metallo-
Nazarov-type cyclization to give the corresponding carbenoid (I) 
and cyclopentenium (II) intermediates of gold (Scheme 1, eq 
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1).[18-21,25] Subsequent acyl elimination or cyclopropanation, for 
substrates bearing an alkene moiety at the R3 position, in these 
putative adducts were then shown to afford the respective 
cyclopentenones 6 and cyclopropa[c]pentalenes 7. In the case 
of the latter, the construction of the cyclopropane motif also 
provided evidence for the involvement of the metallocarbenoid 
species reputedly formed in the course of these reactions. A 
tandem process that allows for the further functionalization of the 
posited in situ generated cyclopentenyl gold complex II and 
access to a potentially wider scope of cycloisomerization 
products, by contrast, has not been examined.[19] In this context 
and as part of studies examining the utility of gold catalysis in 
organic chemistry,[24] we queried whether a suitably placed N-
tethered C=C bond could trap such organogold intermediates. If 
so, it would be anticipated that the formation of new bicyclic 
derivatives containing a fused N-heterocyclic motif might ensue. 
Herein, we report the realization of this concept with the 
development of an expedient and chemoselective synthetic 
route to 3a,6-methanoisoindole esters 8 as a single regio- and 
diastereomer from Au(I)-catalyzed cycloisomerization/Diels Alder 
reaction of 1,4,9-dienyne esters 5 (Scheme 1, eq 2).[22,23] In 
instances starting with a chiral 1,4,9-dienyne ester, the 
norbornane-fused pyrrolidine was additionally obtained as single 
enantiomer with four stereogenic centers that illustrated the 
reaction to proceed with efficient transfer of chirality from the 
enantioenriched substrate to the product. A study that delineates 
one example to exhibit potent antagonist activity toward TNF--
TNFR1 binding and TNF--induced NF-B activation at an IC50 
value of 6.6 M is also presented. Included in this investigation 
are our findings demonstrating the low cytotoxicity of the 
isoindolyl derivative toward HepG2 cells and its likely mode of 
interaction by employing molecular modeling calculations. 
 
Scheme 1. Au(I)-Catalyzed Reactivities of 1,3- and 1,4-Enyne Esters 
Results and Discussion 
Our studies commenced by evaluating the gold-catalyzed 
cycloisomerizations of 1,4,9-dienyne acetate 5a to establish the 
reaction conditions (Table 1).[26] This initially revealed treatment 
of the substrate with 5 mol % of Au(I) catalyst A and 4 Å 
molecular sieves (MS) in toluene at 80 °C for 2 h gave 8a in 
96% yield and as a single regio- and diastereomer (entry 1). The 
relative configuration and structure of the 3a,6-methanoisoindole 
adduct was determined by NMR spectroscopic measurements 
and X-ray crystallography.[27] Reducing the reaction temperature 
from 80 °C to room temperature gave a lower product yield of 
82% (entry 2). Likewise, either lower or comparable product 
yields of 76-99% were observed when the reaction was 
repeated with Au(I) phosphine complexes B-E, NHC-gold(I) 
(NHC = N-heterocyclic carbene) complexes F-H, PPh3AuNTf2, 
AuCl or AuCl3 in place of A as the catalyst (entries 3-8 and 10-
12). Our studies subsequently revealed reaction of 5a mediated 
by 5 mol % of NHC-gold(I) complex H and 4 Å MS in toluene at 
80 °C for 2 h provided the best result, affording 8a in near 
quantitative yield (entry 9). In addition, the use of the conditions 
described in entries 11 and 12 using AuCl or AuCl3 as the 
catalyst were shown to be ineffective at mediating the reactions 
of other substrates (vide infra). With NHC-gold(I) complex H as 
the catalyst, further control reactions with THF, MeCN or 1,2-
dichloroethane in place of toluene as the solvent was found to 
furnish lower product yields of 76-95% (entries 13-15). In 
contrast, the analogous control experiment catalyzed by PtCl2 
was the only instance that gave a low product yield of 50% 
(entry 16). 
 
Table 1. Optimization of the Reaction Conditions[a] 
 
entry catalyst solvent time (h) yield (%)b 
1 A PhMe 2 96 
2c A PhMe 17 82 
3 B PhMe 17 93 
4 C PhMe 17 76 
5 D PhMe 3 93 
6 E PhMe 2 91 
7 F PhMe 3 95 
8 G PhMe 2 96 
9 H PhMe 2 99(99)d 
10 Ph3PAuNTf2 PhMe 5 95 
11 AuCl PhMe 5 97 
12 AuCl3 PhMe 3 93 
13 H THF 8 95 
14 H MeCN 4 91 
15 H (CH2Cl)2 5 76 
16 PtCl2 PhMe 17 50 
[a] All reactions were performed at the 0.3 mmol scale with catalyst:5a 
ratio = 1:20 and 4 Å MS (300 mg) at 80 °C in given solvent and time. [b] 
1H NMR yield with CH2Br2 as the internal standard. [c] Reaction carried 
out at room temperature. [d] Value in parentheses denotes isolated 
product yield. 
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Summarized in Table 2 are the results of the scope of the 
present procedure that were assessed by examining the 
reactions of a variety of 1,4,9-dienyne esters. Overall, these 
studies revealed that with Au(I) complex H as the catalyst, the 
reaction conditions proved to be general and a variety of 3a,6-
methanoisoindole esters could be furnished in 40-99% yield 
from the corresponding substrates 5b-x. Reactions of substrates 
containing a Bz (5b) instead of an Ac migrating group or a 
cycloalkyl (5c,d) or benzyl (5e,f) moiety in place of the methyl 
substituent at the acetate carbon center were found to proceed 
to give 8b-f in 85-99% yield. The presence of various 
substitution patterns on the allylic amine side chain of the tertiary 
acetate (5g-5v) was found to have no influence on the course of 
the reaction. Under the standard conditions, these experiments 
gave the corresponding nitrogen-containing tricyclic products 
8g-8v in 40-99% yield. Pleasingly, this included starting acetates 
containing a benzyl ether (5j,l), OTBS (5k,m), 2-furanyl (5s) or 
2-thiophenyl (5t) moiety, showing that such functional groups 
were well tolerated under the reaction conditions. Added to this 
is the construction of one example containing a tetrafused ring 
motif (8o) from the corresponding substrate bearing a pendant 
cyclohexenyl ring (5o). Likewise, reactions of secondary 
carboxylic esters (5w,x) were found to give the corresponding 
3a,6-methanoisoindole esters 8w and 8x in 48 and 67% yield, 
respectively. Moreover, in all the above transformations, the 
cycloisomerization process was shown to occur in a highly 
selective manner with the bridged N-heterocycle being obtained 
 
Table 2. Cycloisomerization of 5b-x Catalyzed by NHC-Au(I) Complex H[a] 
 
[a] All reactions were performed at the 0.3 mmol scale with H:5 ratio = 1:20 
and 4 Å MS (300 mg) in toluene at 80 °C for 1-17 h. Values in parentheses 
denote isolated product yields.  
as a single diastereo- and regioisomer. Other than a number of 
unidentifiable decomposition products, no other cycloadducts 
that could be formed from cyclopropanation or deacylation of the 
putative pentacyclic intermediate were detected by 1H NMR 
spectroscopic analysis of the crude mixtures.[17,18] In addition, 
the structure and relative diastereochemistry of 8g, 8k, 8n and 
8p were confirmed by X-ray crystallographic analysis.[27] As 
shown in Scheme 2, this was further exemplified by repeating 
the Au(I)-catalyzed rearrangement of enantioenriched ent-5v 
prepared from the corresponding 1,6-enyne (ent-S1v) with an ee 
value of 96%.[26] Subsequent K2CO3-mediated deacylation of the 
resulting tricyclic adduct ent-8v, obtained in 77% yield, in 
methanol provided ent-9v in 93% yield and with an ee value of 
96%. The (1S,3aS,5S,6S,7aS) absolute stereochemistry of the 
chiral isoindolyl compound was ascertained by X-ray single 
structure crystallography.[27] 
 
Scheme 2. Cycloisomerization of ent-5v Catalyzed by NHC-Au(I) Complex H  
A plausible mechanism for the present Au(I)-catalyzed 3a,6-
methanoisoindole ester forming reaction is outlined in Scheme 
3. Using 5a as a representative example, the first step could 
involve activation of the alkyne moiety of the carboxylic ester in 
the substrate by the Au(I) catalyst. The Au(I)-coordinated 
complex IIIa might then become prone to syn 1,2-acyloxy 
migration to produce the putative vinyl gold adduct Va via 1,3-
dioxin-1-ium intermediate IVa (Scheme 3, path a).[28] 
Subsequent metallo-Nazarov-type cyclization of this newly 
formed organogold species followed by deauration of the 
ensuing cyclopentenium intermediate IIa that was put forward in 
Scheme 1, eq 2, would give the cyclopentadiene VIa. 
Alternatively, the carbocyclic 1,3-diene intermediate might be 
generated directly from metallo-Nazarov-type cyclization of IVa 
upon its formation followed by deauration of IIa (Scheme 3, path 
b).[15i] Diels-Alder reaction of the cyclopentadiene intermediate 
generated by one of these two possible mechanistic pathways 
 
Scheme 3. Proposed Mechanism for Au(I)-Catalyzed Rearrangement of 1,4,9-
Dienyne Esters Represented by 5a 
FULL PAPER    
 
 
 
 
 
might consequently deliver the product 8a. For the reaction 
involving enantioenriched ent-5v, the observed stereochemistry 
at the newly formed chiral centers in the product could be due to 
the stereogenic benzyl position in the substrate directing the 
Diels-Alder reaction to occur at the sterically less hindered 
opposite face of the alkene bond to the aryl group. The 
proposed involvement of the cyclopentadiene intermediate VIa 
would also be in good agreement with our findings for the control 
experiment shown in Scheme 4. Treatment of 5a with 5 mol % of 
Au(I) complex H and 4 Å MS in toluene at room temperature for 
30 min provided the cyclopentadiene adduct 10a (VIa in Scheme 
3) as the only product in 74% yield. Further subjecting the 
cycloadduct in toluene to a reaction temperature of 80 °C for 4 h 
then gave the expected isoindole product 8a in 80% yield. 
 
Scheme 4. Control Experiment with 5a 
Prompted by the presence of the indolyl motif in the TNF- 
inhibitors 2,[9] 3[10] and SPD304[7] shown in Figure 1, we next 
queried whether the isoindolyl adducts prepared in this work 
would exhibit this type of bioactivity. With this in mind, a TNF-
enzyme-linked immunosorbent assay (ELISA) was performed 
with compounds 8a-8x at a concentration of 100 M (Figure 2 
and Figure S1 in the SI). This test revealed the isoindolyl 
derivative 8i to be the most effective at inhibiting TNF--TNFR1 
binding. At the same concentration, the positive control 
experiment with SPD304, the most potent small molecule TNF-
inhibitor reported to date, was shown to be about three times 
less active. This was further supported by dose-response ELISA 
experiments aimed at determining the IC50 values of these 
compounds against TNF--TNFR1 interaction (Figure 3). Under 
our test conditions, isoindole 8i was shown to exhibit 
concentration-dependent inhibition of TNF--TNFR1 binding, 
with an approximate IC50 value of 2.6 M. This compared 
favorably to an IC50 ≈ 23 M found for SPD304 and the reported 
literature value of about 22 M for the indole-tethered 
chromone.[7] 
 
Figure 2. Compound inhibition of TNFR1 binding to immobilized TNF- 
(ELISA). Microtiter plates coated with TNF- were incubated with TNFR1 
together with compounds 8a-8x or SPD304 at the indicated concentration. 
TNFR1 binding was detected using anti-TNFR1 antibody and horseradish 
peroxidase-conjugated secondary antibody. Error bars represent the standard 
deviations of the results from three independent experiments. 
 
Figure 3. Dose-dependent compound inhibition of TNFR1 binding to 
immsobilized TNF- (ELISA). Microtiter plates coated with TNF- were 
incubated with TNFR1 together with compound 8i or SPD304 at the indicated 
concentrations. TNFR1 binding was detected using anti-TNFR1 antibody and 
horseradish peroxidase-conjugated secondary antibody. Approximate IC50 
values: 8i: 2.6 µM, SPD304: 23 µM. Error bars represent the standard 
deviations of the results from three independent experiments. 
The ability of 8i to attenuate NF-B transcriptional activity 
through inhibition of TNF- signaling in a HepG2 cell line was 
also investigated. TNF- was pre-incubated with different 
concentrations of the isoindolyl adduct or SPD304 prior to its 
addition to HepG2 cells stably transfected with the NF-B-
luciferase (NF-B-Luc) reporter gene (Figure 4). By monitoring 
the reduction in the luciferase activity of the cell lysates, this test 
revealed the isoindolyl derivative inhibited TNF--induced NF-B 
activation in a dose-dependent manner, with an IC50 value of 
about 6.6 M. This indicated 8i was slightly more active than 
SPD304, which gave an IC50 of approximately 25 M in a side-
by-side assay. More importantly, using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay, the bridged N-heterocycle was shown to exhibit only 
moderate inhibition of HepG2 cells, as witnessed by an IC50 
value of more than 100 M (Figure 5). This suggested 8i is 
relatively non-cytotoxic toward this in vitro cell line and, thus, has 
potential for further development as an anti-inflammatory drug 
candidate. 
 
Figure 4. Dose-dependent compound inhibition of cellular TNF--induced NF-
B activity. HepG2 cells stably transfected with the NF-B-Luc reporter gene 
were stimulated with TNF-pre-incubated with the indicated concentrations of 
8i or SPD304. Cell lysates were analyzed for firefly luciferase activity to 
determine the extent of NF-B inhibition. Approximate IC50 values: 8i: 6.6 M, 
SPD304: 25 M. Error bars represent the standard deviations of the results 
from three independent experiments. 
To gain an insight into the mechanism of action of 8i as an 
antagonist toward TNF--TNFR1 binding, we employed 
molecular modeling to analysis the interaction between the small 
molecule and TNF- (Figure 6). The initial model of TNF- was 
built from the X-ray crystal structure of its dimer with SPD304 
(PDB code: 2AZ5)[7] with the binding interaction being evaluated 
using the Molsoft ICM method (ICM-Pro 3.6-1d molecular  
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Figure 5. Dose-dependent effect of inhibition on cell viability in HepG2 cells 
exhibited by 8i. HepG2 cells were treated with the cycloadduct 8i at the 
indicated concentrations for 72 h. Cell viability was determined by measuring 
the color intensity at 570 mm. IC50 = >100 M. Error bars represent the 
standard deviations of the results from three independent experiments. 
docking software).[29] The geometry of the isoindolyl derivative 
was optimized using density functional theory (DFT) calculations 
and the small molecule was docked to a grid representation of 
the receptor and assigned a score reflecting the quality of the 
complex. In the lowest-energy binding pose, the N-heterocycle 
was observed to be located at the hydrophobic binding pocket at 
the protein-protein interface of the TNF- dimer (Figure 6a). The 
cycloadduct closely contacts the residues of the -strand 
(Leu120-Gly121-Gly122) of TNF- subunit A, with its relatively 
more polar acetate and tosylate functional groups orientated 
away from the binding pocket and exposed to the aqueous 
environment. Furthermore, the isoindole appeared to be situated 
slightly further from TNF- subunit B compared to SPD304, 
which is predicted to lie an approximately equal distance from 
both subunits (Figure 6b). The lack of salt bridges or hydrogen- 
bonding networks in our models of 8i and SPD304 with TNF- 
suggest that the interaction between the small molecules and 
TNF- is primarily hydrophobic and shape-driven, consistent 
with previous findings. As can be seen in the superposition of 8i 
and SPD304 with the TNF- dimer shown in Figure 6c, both 
molecules are large enough to simultaneously contact both 
subunits of the TNF-. This presumably prevents the binding of 
the third subunit to form the biologically active trimer complex, 
thus accounting for the observed anti-TNF- activity of the 
isoindolyl derivative. 
Conclusions 
In summary, we have developed a synthetic strategy to 
construct 3a,6-methanoisoindole esters that relied on gold(I)-
catalyzed cycloisomerization of 1,4,9-dienyne esters. The 
transformation was shown to tolerate a diverse set of carboxylic 
ester substrates to efficiently furnish stereochemically well-
defined norbornane-fused pyrrolidines. The efficacy of the 
substituted N-heterocycles at inhibiting TNF- was 
demonstrated by using a TNF--TNFR1 binding ELISA and a 
cell-based luciferase reporter assay. Notably, one example was 
shown to possess superior potency at inhibiting TNF- 
compared to the positive control compound SPD304 in the in 
vitro assays. The isoindolyl derivative was also found to be 
relatively non-cytotoxic in a HepG2 cell line study while 
molecular docking analysis suggested that it bound to the 
protein-protein interface of the TNF- dimer primarily via 
hydrophobic interactions. Taken together, these results 
demonstrate the potential of this new class nitrogen-containing 
heterocyclic compounds as promising lead structures for the 
development of more potent TNF- inhibitors. 
 
a 
 
b 
 
c 
Figure 6. As generated by virtual ligand docking, low-energy binding pose of: 
(a) compound 8i to the TNF- dimer; (b) SPD304 to the TNF- dimer; and (c) 
superposition of 8i (white) and SPD304 (blue) bound to the TNF- dimer. In 
each figure, the small molecules are shown in ball-and-stick form and the 
TNF-dimer is shown in ribbon form. 
Experimental Section 
To a solution of 1,4,9-dienyne ester 5 (0.3 mmol) and 4 Å MS (300 mg) in 
toluene (3 mL) was added NHC-gold(I) complex H (15 mol, 13 mg) 
under an argon atmosphere. The resulting solution was heated 80 °C 
and the reaction was monitored by thin layer chromatography. Upon 
completion, the reaction mixture was cooled to room temperature, filtered 
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through a pad of Celite, washed with EtOAc (10 mL) and the solvent was 
removed under reduced pressure. Purification by flash column 
chromatography on silica gel (n-hexane/ EtOAc = 9:1 as eluent) gave the 
product 8. 
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